Cresilon has developed innovative hemostatic technologies aimed at rapidly controlling bleeding in both veterinary and human medical applications. Their flagship product, VETIGEL®, is a single-use gel designed specifically for veterinary use, which achieves hemostasis in seconds upon contact with a wound. This plant-based gel is composed of proprietary polymers derived from non-animal sources, making it biocompatible and safe for use in animals. VETIGEL® eliminates the need for manual pressure, as it creates a mechanical seal that effectively stops bleeding, thereby revolutionizing the standard of care in emergency veterinary situations.

In addition to VETIGEL®, Cresilon has introduced TRAUMAGEL, a groundbreaking product derived from algae that is designed for human trauma care. TRAUMAGEL is engineered to stop severe bleeding in critical injuries, such as gunshot wounds and stabbings, within seconds. The gel forms a mechanical barrier upon contact with the wound, which allows for effective bleeding control without the need for manual pressure. With FDA clearance for both VETIGEL® and TRAUMAGEL, Cresilon is positioned to significantly impact emergency medical care, potentially saving countless lives by providing rapid and effective solutions for bleeding control.

United States

Headquartered in Brooklyn, New York, Cresilon, Inc. is a privately-held medical device company focused on hemostatic technologies that improve wound care and advance the standard of medical treatments. For more information, visit Cresilon.com. 

We are always looking for dynamic people to join our team as we dive into a range of challenges at the forefront of science and technology—to learn more about our openings please visit https://cresilon.workable.com/.

Cresilon

Company Details